Fig. 5: Serum from mice immunized with RBD-CLP vaccines neutralizes SARS-CoV-2 in vitro. | Nature Communications

Fig. 5: Serum from mice immunized with RBD-CLP vaccines neutralizes SARS-CoV-2 in vitro.

From: Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Fig. 5: Serum from mice immunized with RBD-CLP vaccines neutralizes SARS-CoV-2 in vitro.The alternative text for this image may have been generated using AI.

a Serum from groups of mice (n = 4) immunized (prime 1ug/boost 1 ug) with RBDc-CLP (orange) (n = 4) or soluble RBDc (prime 2 ug/boost 2 ug) (blue) was mixed with a SARS-CoV-2 virus and tested for cell entry. Each dot represents the percentage neutralization per mouse per dilution. Bars represent the mean and standard deviation. b, c Serum from groups of mice (n = 4) immunized (prime 6.5 µg/boost <0.1 µg/boost 6.5 µg) with RBDn-CLP obtained after the first (b) or last (c) immunization was mixed with a SARS-CoV-2 virus and tested for cell entry. Each dot represents the percentage neutralization per mouse per dilution. Bars represent the mean and SD. d Correlation between ELISA IgG endpoint titer (2nd bleed, cutoff 0.2) and the serum dilution required for 50% virus neutralization. The ELISA endpoint titers and the 50% neutralization titers were measured on the same set of serum samples obtained from groups of mice (n = 4) immunized with RBDc (n = 4), RBDc-CLP (n = 4), RBDn (n = 4) or RBDn-CLP (n = 4) (Fig. 4a–c). Each dot represents one mouse. A Pearson r correlation was used to assess the relationship between variables.

Back to article page